Threshold Pharmaceuticals Inc (THLD)

0.47
0.01 1.67
NASDAQ : Health Care
Prev Close 0.48
Open 0.49
Day Low/High 0.45 / 0.49
52 Wk Low/High 0.21 / 5.28
Volume 355.32K
Avg Volume 1.94M
Exchange NASDAQ
Shares Outstanding 71.56M
Market Cap 34.35M
EPS 0.60
P/E Ratio 0.30
Div & Yield N.A. (N.A)

Latest News

Caris Life Sciences And Threshold Pharmaceuticals Collaborate To Utilize Caris' ADAPT Biotargeting System In The Development Program For Evofosfamide

Caris Life Sciences And Threshold Pharmaceuticals Collaborate To Utilize Caris' ADAPT Biotargeting System In The Development Program For Evofosfamide

Caris Life Sciences to Develop a Customized Assay for Pancreatic Cancer Patients to Predict Likelihood of Response to Evofosfamide, Threshold Pharmaceutical's Lead Drug Product Candidate

One Reason Why Threshold Pharma (THLD) Stock Is Jumping Today

One Reason Why Threshold Pharma (THLD) Stock Is Jumping Today

Threshold Pharma (THLD) stock is advancing on Monday afternoon alongside other biopharma stocks as fellow drug maker Medivation (MDVN) agreed to be bought by Pfizer (PFE) for $14 billion.

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering breakout trades.

Threshold Pharmaceuticals Highlights Multiple Presentations At The 2016 ASCO Annual Meeting

Threshold Pharmaceuticals Highlights Multiple Presentations At The 2016 ASCO Annual Meeting

Presentation of additional subset data from Phase 3 MAESTRO trial of evofosfamide in pancreatic cancer demonstrates meaningful improvement in overall survival in patients from Asia; risk of death reduced by almost 50 percent

Threshold Pharmaceuticals To Present At Jefferies 2016 Healthcare Conference

Threshold Pharmaceuticals To Present At Jefferies 2016 Healthcare Conference

Company Presentation Scheduled for June 7, 2016 at 3:30 p.m. ET

CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail

CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail

Data from CytRx's phase III study of aldoxorubicin for the treatment of patients with soft-tissue sarcoma are being analyzed right now, with results expected toward the end of June.

Short Interest Moves 50% Lower For THLD

Short Interest Moves 50% Lower For THLD

The most recent short interest data has been released by the NASDAQ for the 12/15/2015 settlement date, which shows a 3,873,247 share decrease in total short interest for Threshold Pharmaceuticals Inc , to 3,862,114, a decrease of 50.07% since 11/30/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

2 'Rules of the Road' for Biotech Investing

Follow these maxims and you should do well in this volatile sector.

Why Relypsa Is a New 'Best Idea'

It is hard to see the biotech firm not becoming a takeover target.

Threshold Pharmaceuticals (THLD) Weak On High Volume

Threshold Pharmaceuticals (THLD) Weak On High Volume

Trade-Ideas LLC identified Threshold Pharmaceuticals (THLD) as a weak on high relative volume candidate

Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics

Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics

TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.

First Week of THLD January 2016 Options Trading

First Week of THLD January 2016 Options Trading

Investors in Threshold Pharmaceuticals Inc saw new options begin trading this week, for the January 2016 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the THLD options chain for the new January 2016 contracts and identified one put and one call contract of particular interest.

Threshold Pharmaceuticals (THLD) Is Weak On High Volume Today

Threshold Pharmaceuticals (THLD) Is Weak On High Volume Today

Trade-Ideas LLC identified Threshold Pharmaceuticals (THLD) as a weak on high relative volume candidate

My Wall Street Fantasy Football League

If there were a Super Bowl for stocks, these companies could win.

Strong On High Volume: Threshold Pharmaceuticals (THLD)

Strong On High Volume: Threshold Pharmaceuticals (THLD)

Trade-Ideas LLC identified Threshold Pharmaceuticals (THLD) as a strong on high relative volume candidate

First Week Of THLD March 2016 Options Trading

First Week Of THLD March 2016 Options Trading

Investors in Threshold Pharmaceuticals Inc saw new options begin trading this week, for the March 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Threshold Pharmaceuticals (THLD) Stock Soars on FDA Fast Track Designation

Threshold Pharmaceuticals (THLD) Stock Soars on FDA Fast Track Designation

Threshold Pharmacueticals (THLD) shares spike after being granted fast track designation for pancreatic cancer treatment.

Take Aim at Threshold Pharmaceuticals

A small biotech gem with lots of potential.

Threshold Pharmaceuticals Stock Sees Short Interest Drop 21.8%

Threshold Pharmaceuticals Stock Sees Short Interest Drop 21.8%

The most recent short interest data has been released by the NASDAQ for the 02/27/2015 settlement date, which shows a 1,500,046 share decrease in total short interest for Threshold Pharmaceuticals Inc , to 5,392,887, a decrease of 21.76% since 02/13/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

3 Biotech Stocks Under $10 in Breakout Territory: TrovaGene and More

3 Biotech Stocks Under $10 in Breakout Territory: TrovaGene and More

These under-$10 biotech stocks are within range of triggering breakout trades.

Biotech Stock Mailbag: Threshold, Galena, CytRx

Biotech Stock Mailbag: Threshold, Galena, CytRx

Biotech columnist Adam Feuerstein answers readers' questions about health care.

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.